Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3Gynecologic 2Genitourinary 2Head & Neck 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1

Interventions

Oxaliplatin 1004Fluorouracil 800Capecitabine 765Gemcitabine 651Leucovorin 559Irinotecan 537Bevacizumab 513Radiotherapy 460Cisplatin 441Drug Therapy 298Cetuximab 280Surgical Procedures, Operative 229Paclitaxel 228S 1 (combination) 218pembrolizumab 206Docetaxel 199130-nm albumin-bound paclitaxel 196Nivolumab 193sintilimab 191Radiosurgery 190lenvatinib 181Folfox protocol 179Sorafenib 178Albumin-Bound Paclitaxel 173apatinib 170tislelizumab 161camrelizumab 160Neoadjuvant Therapy 158Blood Specimen Collection 154durvalumab 148

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × RC48 antibody × Gastrointestinal × Clear all
NCT05241899 2022-02-16

A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Cancer

The First Affiliated Hospital of Zhengzhou University

Phase 2 Unknown
56 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡